Establishment Labs Expands Breast Tissue Preservation Portfolio with New Data and Product Extensions
Event summary
- Establishment Labs presented new clinical data on Breast Tissue Preservation at the 11th World Symposium on Ergonomic Implants (WSEI) in Istanbul, Turkey.
- The company announced product line extensions for Mia® and Preservé™, including new sizes and supporting tools.
- The Breast Tissue Preservation Building Blocks Supplement was published in the Aesthetic Surgery Journal, featuring contributions from 25 authors.
- CEO Peter Caldini highlighted an 11% growth in the breast augmentation market, attributing it to the company's innovations.
The big picture
Establishment Labs' announcements at WSEI underscore the growing emphasis on minimally invasive and tissue-preserving technologies in breast aesthetics. The 11% market growth highlighted by the American Society of Plastic Surgeons suggests a favorable environment for innovative solutions. The company's focus on scientific validation and product expansion positions it to capitalize on this trend, though execution and regulatory hurdles remain critical factors.
What we're watching
- Market Expansion
- How the new product sizes and tools will affect Establishment Labs' market penetration and competitive positioning.
- Clinical Validation
- Whether the published data in the Aesthetic Surgery Journal will accelerate adoption of the Minimally Invasive Platform.
- Regulatory Approvals
- The pace at which Establishment Labs can secure regulatory clearances for its expanded product line.